Open-Label, Dose-Escalating, Phase I Study of TG4040 (MVA-HCV) in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (HCV Genotype 1).
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2011
At a glance
- Drugs TG 4040 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 24 Aug 2011 Added purpose and treatment tables
- 23 Aug 2011 Results published in the Nature Reviews Gastroenterology and Hepatology journal and the Gastroenterology journal, according to a Transgene media release.
- 02 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.